NIH, Drug Industry Target Barriers to Patient Accrual in Clinical Trials

Publication
Article
OncologyONCOLOGY Vol 16 No 10
Volume 16
Issue 10

A new partnership between the National Institutes of Health and five major drug companies will provide a total of $6 million to several cancer centers to find ways to increase accrual to early clinical trials. The five pharmaceutical firms involved in the

A new partnership between the National Institutes of Health andfive major drug companies will provide a total of $6 million to several cancercenters to find ways to increase accrual to early clinical trials. The fivepharmaceutical firms involved in the pilot program are Aventis, Bristol-MyersSquibb, Eli Lilly and Co, GlaxoSmithKline, and Novartis. The National CancerInstitute (NCI) intends to award funds only to clinical and comprehensive cancercenters that it supports, because these institutions have the infrastructure inplace to conduct early-phase trials at the community level. Applicants willcompete for a share of approximately $3 million annually for 2 years. Half thatamount will come from the NCI and the other half from industry. The effort isnot intended to expand existing programs or systems at NCI cancer centers but toencourage novel solutions to overcome existing barriers to trial accruals andincrease the performance of the existing systems.

Recent Videos
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
Related Content